Diagnosing and treating hematopoietic cancers
First Claim
Patent Images
1. A method of determining whether a subject has, or is at risk of developing, a hematopoietic cancer associated with a reduction in wingless-related MMTV integration site 5a (Wnt5a) gene expression or activity or protein activity, the method comprising:
- providing a biological sample comprising a test cell from the subject; and
determining the level of Wnt5a gene expression or activity or protein activity within the test cell, wherein a reduction in the level of Wnt5a gene expression or activity or protein activity in the test cell, relative to that in a control cell, indicates that the subject has, or is at risk of developing, a hematopoietic cancer.
1 Assignment
0 Petitions
Accused Products
Abstract
Described herein are methods and compositions comprising Wnt5a for the diagnosis and treatment of hematopoietic cancers, and methods of identifying therapeutic compounds for the treatment of hematopoietic cancers.
20 Citations
32 Claims
-
1. A method of determining whether a subject has, or is at risk of developing, a hematopoietic cancer associated with a reduction in wingless-related MMTV integration site 5a (Wnt5a) gene expression or activity or protein activity, the method comprising:
-
providing a biological sample comprising a test cell from the subject; and
determining the level of Wnt5a gene expression or activity or protein activity within the test cell, wherein a reduction in the level of Wnt5a gene expression or activity or protein activity in the test cell, relative to that in a control cell, indicates that the subject has, or is at risk of developing, a hematopoietic cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A method of identifying an anti-hematopoietic cancer agent, the method comprising:
-
exposing a sample comprising a Wnt5a-expressing cell to a test agent; and
determining the level of Wnt5a gene expression or activity or protein expression or activity in the Wnt5a-expressing cell, wherein an increase in Wnt5a gene expression or activity, or protein expression or activity, relative to the level of Wnt5a gene expression or activity, or protein expression or activity, in a control cell, indicates that the test agent is an anti-cancer agent. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 22)
-
- 23. A method of treating a subject who has, or who is at risk of developing, a Wnt5a-associated hematopoietic cancer, the method comprising administering to the subject a nucleic acid molecule comprising a sequence that encodes Wnt5a or a biologically active fragment or mutant thereof, and, optionally, a sequence that encodes a detectable marker, wherein the amount of the nucleic acid molecule delivered is sufficient to generate a therapeutically effective amount of Wnt5a.
Specification